In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 75 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Breast cancer guidelines	NICE guideline	TBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448	Technology appraisal guidance	TBC
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]	Technology appraisal guidance	5 November 2025
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	11 September 2025
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Technology appraisal guidance	19 November 2025
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance	TBC
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)	Health technology evaluation	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580	Technology appraisal guidance	30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]	Highly specialised technology	17 September 2025
Chronic heart failure in adults: diagnosis and management	NICE guideline	3 September 2025
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]	Technology appraisal guidance	TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment	Health technology evaluation	TBC
Colon cancer (adjuvant) - irinotecan [ID379]	Technology appraisal guidance	TBC
Compression products for treating venous leg ulcers: late stage assessment	Health technology evaluation	27 August 2025
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis	Interventional procedures guidance	TBC

Results per page

10
25
50
All